Jounce Therapeutics, Inc. Common Stock
JNCE
JNCE was delisted on the 3rd of May, 2023.
85 hedge funds and large institutions have $176M invested in Jounce Therapeutics, Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 29 increasing their positions, 19 reducing their positions, and 14 closing their positions.
626% more call options, than puts
Call options by funds: $3.94M | Put options by funds: $543K
53% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 19
14% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 14
2% more funds holding
Funds holding: 83 → 85 (+2)
16% less capital invested
Capital invested by funds: $210M → $176M (-$34.6M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$1.98M |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$1.51M |
| 3 |
Man Group
London,
United Kingdom
|
+$1.49M |
| 4 |
Renaissance Technologies
New York
|
+$1.24M |
| 5 |
Two Sigma Advisers
New York
|
+$961K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$5.87M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.49M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.56M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$2.34M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
-$766K |
JNCE Hedge Fund Activity: Q3 2018 in Review
85 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Jounce Therapeutics, Inc. Common Stock (JNCE) for Q3 2018, worth a combined $176M — down 16% from $210M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new JNCE positions and 14 closed out — a net gain of 2 holders — while 29 added to existing stakes and 19 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $1.98M. The largest seller was Redmile Group, cutting an estimated $5.87M.
- 85 institutional investors held Jounce Therapeutics, Inc. Common Stock (JNCE) as of Q3 2018, up from 83 in Q2 2018.
- Funds reported $176M of Jounce Therapeutics, Inc. Common Stock stock for Q3 2018, down 16% quarter-over-quarter.
- 16 funds opened new Jounce Therapeutics, Inc. Common Stock positions in Q3 2018 and 14 closed out, a net change of +2 holders.
- The largest Jounce Therapeutics, Inc. Common Stock buyer in Q3 2018 was JP Morgan Chase, an estimated $1.98M added.
- The largest Jounce Therapeutics, Inc. Common Stock seller in Q3 2018 was Redmile Group, an estimated $5.87M sold.
Based on aggregated 13F filings for Q3 2018.